Pharmaceuticals
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (...
2023-10-16 07:48
970
Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023
HONG KONG, Oct. 14, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, the "Group", HKEX stock code: 0460) is pleased to announce that the "Group" was selected as one of the first echelon of enterprises in The ...
2023-10-14 20:09
2531
Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement
CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech company with a breakthrough technology to restore defective blood vessels, announced ...
2023-10-13 23:26
2362
Offering broader access to sustainable and scalable pharma-grade saponin adjuvants
SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment to expand Q-Vant's proprietary 100% sustainable Q-SAP™ technology, and the signing of an exclusive commercial agreement to accelerate global adoption of their high-purity saponin adjuvants ...
2023-10-13 21:47
2518
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Acti...
2023-10-13 20:00
2013
Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata
* IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile * IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD) * An interim data readout in AA is expected in Q3 20...
2023-10-13 20:00
1352
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
New data presented on novel orally bioavailable p300-selective degraders showing significant anti-tumor activity in preclinical models of androgen receptor (AR) positive prostate cancer SEOUL, South Korea and KING OF PRUSSIA, Pa., Oct. 12, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global bio...
2023-10-13 09:00
1330
GenScript ProBio Congratulates ABL Bio's IND Clearance of ABL103 Program from MFDS
SEOUL, South Korea, Oct. 13, 2023 /PRNewswire/ -- Recently, ABL Bio, a partner of GenScript ProBio, announced the Ministry of Food and Drug Safety (MFDS) cleared of its clinical trial application for innovative bispecific antibody program (B7H4x4-1BB) in solid tumor. GenScript ProBio warmly exten...
2023-10-13 09:00
1870
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy
.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone1 .. Phase 3 results expected in 2025 .. Exclusive license for AU, NZ, Singapore, Mal...
2023-10-13 03:00
1833
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival
SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in th...
2023-10-12 20:50
1403
Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)
HONG KONG, Oct. 12, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") announced that the results of the multicenter, open-label Phase Ib/II clinical trial (COMPASSION-03/AK104-201) for cadonilimab (PD-1/CTLA-4 bispecific antibody), the globally first bispecific IO drug used to treat advanced s...
2023-10-12 20:00
1229
Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research
Metabolon's newest panels help academic and commercial researchers reveal complex biological insights about liver fibrosis and kidney dysfunction MORRISVILLE, N.C., Oct. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of lif...
2023-10-12 19:57
1304
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192
* HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinson's Disease in collaboration with NurrOn Pharmaceuticals. * The Phase 1 Study evaluates the safety, tolerability, and pharmacokinetics of ...
2023-10-12 19:00
1210
Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress
SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has unveiled its phase III clinica...
2023-10-12 18:49
1253
MicuRx announces poster presentation and participation in ID Week 2023 Conference
FOSTER CITY, Calif., Oct. 11, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, announces that a poster on our preclinical product, MRX-6038, will be p...
2023-10-11 23:33
1441
Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
SUZHOU, China, Oct. 11, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional appr...
2023-10-11 17:20
1292
TaiGen Enters Exclusive License Agreement with YSP
TAIPEI, Oct. 10, 2023 /PRNewswire/ -- TaiGen Biopharmaceuticals Holdings Ltd. ("TaiGen") announces that TaiGen Biotechnology, a subsidiary company of TaiGen, have signed an exclusive licensing agreement with Y.S.P. Industries (M) Sdn. Bhd. to develop and commercialize TaiGen's new drug inMalaysia...
2023-10-11 11:24
1426
Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023
HANGZHOU and SHAOXING, China, Oct. 11, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the European Academy of Der...
2023-10-11 08:10
1741
SAFETYscan47: A Valuable Component in Revolutionizing Chemical Risk Assessments for Global Health and Safety
SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, today announced its SAFETYscan®47 platform as a New Approach Methodology (NAM), part of a standardized framework aiming to revolutionize chemical risk a...
2023-10-10 23:10
1637
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
- Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet reached - Patent rights secured for TJ-L14B/ABL503 in Eurasia until 2039 ROCKVILLE, ...
2023-10-10 20:00
1190
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Multiple achievements made in China-Hungary BRI conference
[Picked up by 309 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 281 media titles]
2024-05-03 06:25Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Most Read
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
4389
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
3230
Ferretti's Dazzling Presence at the 2024 Singapore Yachting Festival: Showcasing Evolving Trends in Luxury Yachting
2024-04-28 15:02
2982
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
2024-04-28 09:39
2863
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
2822